Octavian Popescu, MD
Internal Medicine · Pinson, ALNPI 1275843609
Payments from drug & device makers
Across 406 payments — averaging $16.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$870
- AstraZeneca$640
- Boehringer Ingelheim$576
- Amgen$555
- Pfizer$535
- Johnson & Johnson$518
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,584100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 59 | $870 |
| AstraZeneca | 35 | $640 |
| Boehringer Ingelheim | 38 | $576 |
| Amgen | 36 | $555 |
| Pfizer | 34 | $535 |
| Johnson & Johnson | 34 | $518 |
| AbbVie(2 entities) | 29 | $408 |
| Lilly USA, LLC | 20 | $354 |
| GSK | 18 | $308 |
| Exact Sciences | 16 | $278 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $236 |
| Amarin Pharma, Inc. | 11 | $185 |
| Bayer | 9 | $164 |
| Sanofi-aventis U.S. LLC | 6 | $110 |
| Esperion Therapeutics, Inc. | 6 | $104 |
| Merck | 6 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $91 |
| Dexcom, Inc. | 4 | $67 |
| Idorsia Pharmaceuticals US Inc | 4 | $64 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Genentech USA, Inc. | 2 | $44 |
| Novartis | 2 | $43 |
| Antares Pharma, Inc. | 2 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $38 |
| Shield Therapeutics Inc | 2 | $37 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Eisai Inc. | 2 | $31 |
| Biogen | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Astellas Pharma US Inc | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Gilead | 1 | $15 |
How this compares
$6,584 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 167 | $168,083 |
| EliquisApixaban | 132 | $93,960 |
| FarxigaDapagliflozin Propanediol | 151 | $93,699 |
| JardianceEmpagliflozin | 117 | $90,420 |
| MounjaroTirzepatide | 58 | $60,369 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 15 | $53,649 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $48,101 |
| TrulicityDulaglutide | 33 | $32,093 |
| RelistorMethylnaltrexone Bromide | 13 | $30,188 |
| XareltoRivaroxaban | 21 | $20,590 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 33 | $18,932 |
| JanuviaSitagliptin Phosphate | 30 | $18,410 |
| RybelsusSemaglutide | 18 | $17,625 |
| MyrbetriqMirabegron | 29 | $16,380 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $15,933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $870 | $185,709185 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Jentadueto Xr | $576 | $104,685141 claims |
| PfizerEliquis | $535 | $93,960132 claims |
| AstraZenecaFarxiga | $640 | $93,699151 claims |
| Lilly USA, LLCMounjaro, Trulicity | $354 | $92,46291 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $308 | $67,033105 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $236 | $30,18813 claims |
| Johnson & JohnsonXarelto | $518 | $20,59021 claims |
| MerckJanuvia | $101 | $18,41030 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $16,38029 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $110 | $15,93319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Pinson
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.